用于心脏淀粉样变性的靶向核成像探针
Targeted Nuclear Imaging Probes for Cardiac Amyloidosis.
作者信息
Bravo Paco E, Dorbala Sharmila
机构信息
Division of Nuclear Medicine and Molecular Imaging, Department of Radiology, the Noninvasive Cardiovascular Imaging Program, Departments of Medicine (Cardiology) and Radiology, Cardiac Amyloidosis Program, Department of Medicine, Brigham and Women's Hospital, 70 Francis Street, Shapiro 5th Floor, Room 128, Boston, MA, 02115, USA.
出版信息
Curr Cardiol Rep. 2017 Jul;19(7):59. doi: 10.1007/s11886-017-0868-4.
PURPOSE OF REVIEW
The aim of the present manuscript is to review the latest advancements of radionuclide molecular imaging in the diagnosis and prognosis of individuals with cardiac amyloidosis.
RECENT FINDINGS
Technetium labeled bone tracer scintigraphy had been known to image cardiac amyloidosis, since the 1980s; over the past decade, bone scintigraphy has been revived specifically to diagnose transthyretin cardiac amyloidosis. F labeled and C labeled amyloid binding radiotracers developed for imaging Alzheimer's disease, have been repurposed since 2013, to image light chain and transthyretin cardiac amyloidosis. Technetium bone scintigraphy for transthyretin cardiac amyloidosis, and amyloid binding targeted PET imaging for light chain and transthyretin cardiac amyloidosis, are emerging as highly accurate methods. Targeted radionuclide imaging may soon replace endomyocardial biopsy in the evaluation of patients with suspected cardiac amyloidosis. Further research is warranted on the role of targeted imaging to quantify cardiac amyloidosis and to guide therapy.
综述目的
本手稿旨在综述放射性核素分子成像在心脏淀粉样变性患者诊断和预后评估方面的最新进展。
最新发现
自20世纪80年代以来，人们就知道锝标记的骨显像剂闪烁扫描可用于心脏淀粉样变性成像；在过去十年中，骨闪烁扫描被重新启用，专门用于诊断转甲状腺素蛋白心脏淀粉样变性。自2013年起，为阿尔茨海默病成像开发的氟标记和碳标记淀粉样蛋白结合放射性示踪剂被重新用于轻链和转甲状腺素蛋白心脏淀粉样变性成像。用于转甲状腺素蛋白心脏淀粉样变性的锝骨闪烁扫描以及用于轻链和转甲状腺素蛋白心脏淀粉样变性的淀粉样蛋白结合靶向PET成像正成为高度准确的方法。在疑似心脏淀粉样变性患者的评估中，靶向放射性核素成像可能很快会取代心内膜心肌活检。有必要进一步研究靶向成像在量化心脏淀粉样变性和指导治疗方面的作用。
Zotero 插件